Compare AbbVie Inc (ABBV) vs Cigna Corp (CI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Cigna Corp — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Cigna Corp trades at $289.67 (market cap $75.82B). The key difference: AbbVie Inc is far larger — about 5.9× Cigna Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CI | |
|---|---|---|
Market Cap | $449.91B | $75.82B |
Sector | Health | Health |
52-Week High | $261.07 | $312.00 |
52-Week Low | $184.85 | $244.41 |
Enterprise Value | $513.38B | $98.92B |
Dividend Yield | 2.72% | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Cigna (CI) trades at $286.62, down 0.4% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 11.95 and consistent earnings beats, including Q1 2026 EPS of $7.79 versus $7.60 expected. Revenue grew to $273.85B in 2025, and the company is expanding into AI-driven healthcare services, as highlighted by recent news of Evernorth's Pharmacy Forward initiative (PRNewswire, 2026-07-01).
The outlook is positive given analyst consensus with a $338.91 price target and 73.68% buy ratings. Key risks include regulatory challenges, such as the Tennessee prescription access lawsuit (Reuters, 2026-06-12), and volatility in medical cost trends. The stock offers value with a dividend yield supported by a recent $1.56 payout, but investors should monitor execution in specialty pharmacy expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
